Abeysuriya Shivanti D, Speers David J, Gardiner Jackie, Murray Ronan J
Department of Microbiology, PathWest Laboratory Medicine, Queen Elizabeth II Medical Centre, Nedlands, Western Australia.
Commun Dis Intell Q Rep. 2010 Sep;34(3):342-4.
A 4-year-old fully immunised male presented to a regional hospital in the West Kimberley with fever and lethargy. Blood cultures yielded serogroup B Neisseria meningitidis, resistant to benzylpenicillin (minimum inhibitory concentration (MIC) 1.0 mg/L). The patient was treated with intravenous ceftriaxone and made a complete recovery. Although invasive N. meningitidis isolates with reduced penicillin susceptibility are not uncommon in Australia, this is the first report of a benzylpenicillin-resistant isolate (MIC > 0.5 mg/L) causing invasive disease. As benzylpenicillin is currently recommended as first line empiric and definitive therapy for invasive meningococcal disease, the emergence of penicillin-resistant N. meningitidis disease is of concern and emphasises the importance of ongoing surveillance for antimicrobial resistance.
一名4岁已完成全部免疫接种的男性患儿因发热和嗜睡被送至西金伯利地区医院。血培养分离出B群脑膜炎奈瑟菌,对苄青霉素耐药(最低抑菌浓度(MIC)为1.0 mg/L)。该患者接受了静脉注射头孢曲松治疗并完全康复。尽管在澳大利亚,青霉素敏感性降低的侵袭性脑膜炎奈瑟菌分离株并不罕见,但这是首例由对苄青霉素耐药的分离株(MIC>0.5 mg/L)引起侵袭性疾病的报告。由于目前推荐苄青霉素作为侵袭性脑膜炎球菌病的一线经验性和确定性治疗药物,耐青霉素脑膜炎奈瑟菌病的出现令人担忧,并凸显了对抗菌素耐药性进行持续监测的重要性。